PHIO PHARMACEUTICALS CORP. Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
PHIO PHARMACEUTICALS CORP. (PHIO) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $7.50 per share for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2014-03-28
- PHIO PHARMACEUTICALS CORP. share-based payment arrangement, option, exercise price range, upper range limit for the quarter ending 2013-09-30 was $7.50.
- PHIO PHARMACEUTICALS CORP. share-based payment arrangement, option, exercise price range, upper range limit for the quarter ending 2013-06-30 was $7.50.
- PHIO PHARMACEUTICALS CORP. share-based payment arrangement, option, exercise price range, upper range limit for the quarter ending 2013-03-31 was $7.50.
- PHIO PHARMACEUTICALS CORP. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2013 was $7.50, a 0.00% change from fiscal 2012.
- PHIO PHARMACEUTICALS CORP. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2012 was $7.50.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 3 month | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month |
|---|---|---|
| 2013-12-31 | $7.50 10-K · filed 2014-03-28 | |
| 2013-09-30 | $7.50 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $7.50 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $7.50 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $7.50 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |